Veeva Systems (NYSE:VEEV)

CAPS Rating: 4 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar DLester78 (72.69) Submitted: 9/29/2014 5:59:55 PM : Outperform Start Price: $28.89 VEEV Score: -5.82

Drugs trials are bad um kay?

Recs

0
Member Avatar tes1900 (30.56) Submitted: 9/24/2014 9:22:54 PM : Outperform Start Price: $29.22 VEEV Score: -6.23

I see connections to certain other industries - good potential

Recs

1
Member Avatar TMFTypeoh (80.66) Submitted: 9/13/2014 6:41:41 AM : Outperform Start Price: $31.25 VEEV Score: -12.53

simon erickson piggyback

Recs

0
Member Avatar mjjm1976 (< 20) Submitted: 5/23/2014 11:37:43 PM : Outperform Start Price: $21.26 VEEV Score: +26.10

I like the technicals at this level. The vision of the company is strong, and they are innovating outside of the Salesforce platform, but I am buying solely on technicals. The stock bounced up from what looks like rock bottom at $17.11 I have been buying since that level and believe $22 is the next resistance level. After than I am a holder with a stop-loss at $21, which eyes on $26.

Recs

0

Recs

0
Member Avatar sobek1 (< 20) Submitted: 12/24/2013 12:09:51 AM : Outperform Start Price: $33.39 VEEV Score: -30.15

Cloud services is the way of the future, buy this stock on the pull back.

Recs

3
Member Avatar TMFInnovator (39.41) Submitted: 12/9/2013 11:34:05 AM : Outperform Start Price: $38.20 VEEV Score: -39.31

- Life sciences is an industry that requires lots of regulated documentation. This is the perfect opportunity for a cloud-based SaaS company like Veeva.
- CEO and co-founder is Peter Gassner, who was previously senior vice president of Salesforce.com. Gassner was directly responsible for building the salesforce platform. He knows what he's doing and has a proven track record.
- IPO was in October and this company is still under-the-radar. Putting in the thumbs up before Wall Street catches on.
- The company has already attracted big clients. They already have 33 of the 50 largest pharmaceutical companies as customers. They have grown their customer list at 59%/yr for the past two years.

Will keep an eye on: 1) # of new users, 2) acquisition costs per new user, and 3) average revenue per user (ARPU).

There's lots of growth ahead for Veeva. Outperform.

Recs

1
Member Avatar karlsmq (< 20) Submitted: 11/22/2013 3:28:08 PM : Outperform Start Price: $38.25 VEEV Score: -39.96

very interesting business model,it is profitable and growing at high rate .

Recs

1
Member Avatar dubsac (50.56) Submitted: 11/6/2013 6:03:15 PM : Outperform Start Price: $38.64 VEEV Score: -42.76

Only viable cloud for pharmaceutical and biotech industries.

Results 1 - 9 of 9

Featured Broker Partners


Advertisement